PONTI, Antonio, Guglielmo RONCO, Elsebeth LYNGE, Mariano TOMATIS, Ahti ANTTILA, Nieves ASCUNCE, Mireille BROEDERS, Jean-Luc BULLIARD, Isabella CASTELLANO, Patricia FITZPATRICK, Alfonso FRIGERIO, Solveig HOFVIND, Ondřej MÁJEK, Nereo SEGNAN a Stephen TAPLIN. Low-grade screen-detected ductal carcinoma in situ progresses more slowly than high-grade lesions: evidence from an international multi-centre study. Breast Cancer Research and Treatment. Nizozemí: Springer, 2019, roč. 177, č. 3, s. 761-765. ISSN 0167-6806. Dostupné z: https://dx.doi.org/10.1007/s10549-019-05333-6.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Low-grade screen-detected ductal carcinoma in situ progresses more slowly than high-grade lesions: evidence from an international multi-centre study
Autoři PONTI, Antonio (380 Itálie, garant), Guglielmo RONCO (380 Itálie), Elsebeth LYNGE (208 Dánsko), Mariano TOMATIS (380 Itálie), Ahti ANTTILA (246 Finsko), Nieves ASCUNCE (724 Španělsko), Mireille BROEDERS (528 Nizozemské království), Jean-Luc BULLIARD (756 Švýcarsko), Isabella CASTELLANO (380 Itálie), Patricia FITZPATRICK (372 Irsko), Alfonso FRIGERIO (380 Itálie), Solveig HOFVIND (578 Norsko), Ondřej MÁJEK (203 Česká republika, domácí), Nereo SEGNAN (380 Itálie) a Stephen TAPLIN (840 Spojené státy).
Vydání Breast Cancer Research and Treatment, Nizozemí, Springer, 2019, 0167-6806.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30204 Oncology
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 3.831
Kód RIV RIV/00216224:14110/19:00110970
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1007/s10549-019-05333-6
UT WoS 000485999300023
Klíčová slova anglicky Breast cancer screening; Ductal carcinoma in situ; Low-grade DCIS; Overtreatment
Štítky 14119612, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 16. 10. 2019 15:34.
Anotace
Purpose Nuclear grade is an important indicator of the biological behaviour of ductal carcinoma in situ (DCIS). De-escalation of treatment has been suggested for low-grade DCIS. Our aim is to estimate the relative rate of progression of DCIS by nuclear grade by analysing the distribution of nuclear grade by detection at initial or subsequent screening. Methods We asked International Cancer Screening Network sites to complete, based on their screening and clinical databases, an aggregated data file on DCIS detection, diagnosis and treatment. Results Eleven screening programs reported 5068 screen-detected pure DCIS in nearly 7 million screening tests in women 50-69 years of age. For all programs combined, low-grade DCIS were 20.1% (range 11.4-31.8%) of graded DCIS, intermediate grade 31.0% and high grade 48.9%. Detection rates decreased more steeply from initial to subsequent screening in low compared to high-grade DCIS: the ratios of subsequent to initial detection rates were 0.39 for low grade, 0.51 for intermediate grade, and 0.75 for high grade (p < 0.001). Conclusions These results suggest that the duration of the preclinical detectable phase is longer for low than for high-grade DCIS. The findings from this large multi-centre, international study emphasize that the management of low-grade DCIS should be carefully scrutinized in order to minimize overtreatment of screen-detected slow-growing or indolent lesions. The high variation by site in the proportion of low grade suggests that further pathology standardization and training would be beneficial.
VytisknoutZobrazeno: 26. 4. 2024 16:38